Diligence memo · auto-generated · as of July 3, 2026
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Lexicon Pharmaceuticals, Inc. operates in Pharmaceuticals, based in The Woodlands.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Lexicon Pharmaceuticals, Inc. has raised $446M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $150M on 2014-11-26.
Most recent recorded round closed around 2026-02-02.
Valuation (modeled)modeled
Provath models Lexicon Pharmaceuticals, Inc. at approximately $374M (range $265M–$434M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.42× the median modeled value of Series D+ Pharmaceuticals companies in 2025–2027 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 27 months.
Last raise 5 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 78% of those peers.
Closest niche peers: DBV Technologies S.A., Galecto, Inc., NovaBay Pharmaceuticals, Inc., Pelage Pharmaceuticals, Inc., Triana Biomedicines, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.